{"id":547498,"date":"2021-06-14T17:26:01","date_gmt":"2021-06-14T17:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=547498"},"modified":"2021-06-14T17:26:01","modified_gmt":"2021-06-14T17:26:01","slug":"hodgkins-lymphoma-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-affimed-therapeutics-acd-therapeutics-cstone-pharmaceuticals-and-many-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hodgkins-lymphoma-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-affimed-therapeutics-acd-therapeutics-cstone-pharmaceuticals-and-many-others_547498.html","title":{"rendered":"Hodgkin\u2019s Lymphoma Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Affimed Therapeutics, ACD Therapeutics, Cstone Pharmaceuticals and Many Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1623659845.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Hodgkin&rsquo;s Lymphoma Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Affimed Therapeutics, ACD Therapeutics, Cstone Pharmaceuticals and Many Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1623659845.jpeg\" alt=\"Hodgkin&rsquo;s Lymphoma Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Affimed Therapeutics, ACD Therapeutics, Cstone Pharmaceuticals and Many Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Hodgkin\u2019s Lymphoma Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hodgkins-lymphoma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Hodgkin&rsquo;s Lymphoma<\/a><\/strong> also known as Hodgkin&rsquo;s disease is a type of blood cancer that initiate in the lymphatic system (part of immune system that help to get rid of waste and fight against infections). This disease is the most common type of cancer of lymphatic system. Hodgkin disease originate in the WBCs and grow abnormally and spread beyond the lymphatic system. As the disease progress it invades into other organs and can damage their function. Hodgkin&rsquo;s lymphoma are more common in men than women and affect individuals between the age of 15-40 and above 55 years. The exact etiology of Hodgkin&rsquo;s Lymphoma is not clear however, DNA mutation, and infection of Epstein-Barr virus (EBV), which causes mononucleosis can be the reason behind the development of Hodgkin&rsquo;s lymphoma.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong>Hodgkin&rsquo;s Lymphoma Pipeline Insight, 2021<\/strong>&rdquo; report provides comprehensive insights about <strong>10+ companies and 10+ pipeline drugs<\/strong> in Hodgkin&rsquo;s Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hodgkins-lymphoma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/hodgkins-lymphoma-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hodgkin&rsquo;s Lymphoma Key Players<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Affimed Therapeutics<\/li>\n<li>ACD Therapeutics<\/li>\n<li>Cstone Pharmaceuticals<\/li>\n<li>4SC<\/li>\n<li>TG Therapeutics<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hodgkins-lymphoma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/hodgkins-lymphoma-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Hodgkin&rsquo;s Lymphoma report covers around 10+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Mid-stage products (Phase II and Phase I\/II)<\/li>\n<li>Early-stage products (Phase I\/II and Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hodgkins-lymphoma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Hodgkin&rsquo;s Lymphoma Therapies<\/a> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>AFM 13<\/li>\n<li>Camidanlumab tesirine<\/li>\n<li>Sugemalimab<\/li>\n<li>Resminostat<\/li>\n<li>TGR-1202<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hodgkins-lymphoma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/hodgkins-lymphoma-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Current Hodgkin&rsquo;s Lymphoma Treatment Scenario and Hodgkin&rsquo;s Lymphoma Emerging Therapies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>How many companies are developing Hodgkin&rsquo;s Lymphoma drugs?<\/li>\n<li>How many Hodgkin&rsquo;s Lymphoma drugs are developed by each company?<\/li>\n<li>How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hodgkin&rsquo;s Lymphoma?<\/li>\n<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Hodgkin&rsquo;s Lymphoma therapeutics?<\/li>\n<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?<\/li>\n<li>What are the clinical studies going on for Hodgkin&rsquo;s Lymphoma and their status?<\/li>\n<li>What are the key designations that have been granted to the emerging drugs?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: https:\/\/www.delveinsight.com\/sample-request\/hodgkins-lymphoma-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<br \/> Executive Summary<br \/> Hodgkin&rsquo;s Lymphoma: Overview<br \/> Pipeline Therapeutics<br \/> &bull; Comparative Analysis<br \/> Therapeutic Assessment<br \/> Hodgkin&rsquo;s Lymphoma &ndash; DelveInsight&rsquo;s Analytical Perspective<br \/> In-depth Commercial Assessment<br \/> &bull; Hodgkin&rsquo;s Lymphoma companies&rsquo; collaborations, Licensing, Acquisition -Deal Value Trends<br \/> Hodgkin&rsquo;s Lymphoma Collaboration Deals<br \/> Mid Stage Products (Phase II)<br \/> &bull; Comparative Analysis<br \/> AFM 13:Affimed Therapeutics<br \/> Drug profiles in the detailed report&hellip;..<br \/> Mid Stage Products (Phase II) <br \/> &bull; Comparative Analysis<br \/> Camidanlumab tesirine: ACD Therapeutics<br \/> Drug profiles in the detailed report&hellip;..<br \/> Pre-clinical and Discovery Stage Products<br \/> Drug profiles in the detailed report&hellip;..<br \/> Inactive Products<br \/> &bull; Comparative Analysis<br \/> Hodgkin&rsquo;s Lymphoma Key Companies<br \/> Hodgkin&rsquo;s Lymphoma Key Products<br \/> Hodgkin&rsquo;s Lymphoma- Unmet Needs<br \/> Hodgkin&rsquo;s Lymphoma- Market Drivers and Barriers<br \/> Hodgkin&rsquo;s Lymphoma- Future Perspectives and Conclusion<br \/> Hodgkin&rsquo;s Lymphoma Analyst Views<br \/> Hodgkin&rsquo;s Lymphoma Key Companies<br \/> Appendix<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;<\/strong><strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hodgkins-lymphoma-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-affimed-therapeutics-acd-therapeutics-cstone-pharmaceuticals-and-many-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/hodgkins-lymphoma-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/hodgkins-lymphoma-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/hodgkins-lymphoma-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hodgkins-lymphoma-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-affimed-therapeutics-acd-therapeutics-cstone-pharmaceuticals-and-many-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hodgkin\u2019s Lymphoma Pipeline Hodgkin&rsquo;s Lymphoma also known as Hodgkin&rsquo;s disease is a type of blood cancer that initiate in the lymphatic system (part of immune system that help to get rid of waste and fight against infections). This disease is &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/hodgkins-lymphoma-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-affimed-therapeutics-acd-therapeutics-cstone-pharmaceuticals-and-many-others_547498.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-547498","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/547498","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=547498"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/547498\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=547498"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=547498"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=547498"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}